Glaxo can nail HGS buy with slightly bigger bid, analysts say

GlaxoSmithKline ($GSK) will have to up its offer for Human Genome Sciences ($HGSI) to succeed, analysts said, but only slightly: A $15 bid may win over investors, in comparison with the current $13. Report